Clinical and Molecular Hepatology

"Suk Bae Kim"

Original Article

Viral hepatitis

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study: Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee; Clin Mol Hepatol 2018;24(3):311-318.
Published online June 4, 2018; DOI: https://doi.org/10.3350/cmh.2017.0070

Abstract
PDF

Background/Aims
Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection.
Methods
We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area.
Results
A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients.
Conclusions
A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.

Citations

Citations to this article as recorded by

Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study
Ik Sung Choi, Kwang Min Kim, Sang Goon Shim
Arab Journal of Gastroenterology.2021; 22(1): 23. CrossRef
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
Gut and Liver.2021; 15(3): 440. CrossRef
Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
Pharmacology Research & Perspectives.2021;[Epub] CrossRef
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt I. Drögemöller, Galen E.B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute I. Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
Biomedicine & Pharmacotherapy.2021; 143: 112195. CrossRef
Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
Chi-Ching Chen, Shui-Yi Tung, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Huang-Wei Xu, Chih-Wei Yen, Yi-Hsing Chen, Sheng-Nan Lu, Chao-Hung Hung
Journal of the Formosan Medical Association.2020; 119(1): 532. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(11): 3414. CrossRef
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
Gut and Liver.2020; 14(6): 775. CrossRef
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium
Chung-Feng Huang, Etsuko Iio, Dae Won Jun, Eiichi Ogawa, Hidenori Toyoda, Yao-Chun Hsu, Hiroaki Haga, Shinji Iwane, Masaru Enomoto, Dong Hyun Lee, Grace Wong, Chen-Hua Liu, Toshifumi Tada, Wan-Long Chuang, Ramsey Cheung, Jun Hayashi, Cheng-Hao Tseng, Sato
Hepatology International.2019; 13(5): 587. CrossRef
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi
Gut and Liver.2019; 13(5): 549. CrossRef
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Jong Eun Yeon
Clinical and Molecular Hepatology.2018; 24(3): 294. CrossRef
Ribavirin/sofosbuvir

Reactions Weekly.2018; 1727(1): 247. CrossRef

11,879 View
207 Download
11 Web of Science
Crossref

Case Report

Ruptured duodenal varices arising from the main portal vein successfully treated with endoscopic injection sclerotherapy: a case report: Ha Yan Kang, Won Kyung Lee, Yong Hyun Kim, Byung Woon Kwon, Myung Soo Kang, Suk Bae Kim, Il Han Song; Korean J Hepatol 2011;17(2):152-156.
Published online June 23, 2011; DOI: https://doi.org/10.3350/kjhep.2011.17.2.152

Abstract
PDF

Duodenal varices result from retroperitoneal portosystemic shunts that usually come from the pancreaticoduodenal vein and drain into the inferior vena cava. Because they are a rare but fatal cause of gastrointestinal bleeding, a prompt hemostatic intervention is mandatory. A 62-year-old man who had a history of excessive alcohol consumption presented with massive hematemesis and melena. Emergent endoscopy revealed ruptured varices with an adhering whitish fibrin clot on the postbulbar portion of the duodenum. Abdominal computed tomography demonstrated a cirrhotic liver with venous collaterals around the duodenum and extravasated contrast in the second and third portions. The collaterals originated from the main portal vein and drained via the right renal vein into the inferior vena cava. Endoscopic injection sclerotherapy with cyanoacrylate was successful in achieving hemostasis, and resulted in the near eradication of duodenal varices at a 6-month follow-up.

Citations

Citations to this article as recorded by

New sights in ectopic varices in portal hypertension
K He, K Pang, X Yan, Q Wang, D Wu
QJM: An International Journal of Medicine.2024; 117(6): 397. CrossRef
Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
Mio Tsuruoka, Jun Inoue, Keishi Ouchi, Kaname Uno, Hideaki Itami, Masashi Ninomiya, Tomoaki Iwata, Akitoshi Sano, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Tomoyuki Koike, Atsushi Masamune
Internal Medicine.2023; 62(10): 1467. CrossRef
Small Intestine Varices in Cirrhosis at a High-Volume Liver Transplant Center: A Retrospective Database Study and Literature Review
Claire L. Jansson-Knodell, Gerardo Calderon, Regina Weber, Marwan Ghabril
American Journal of Gastroenterology.2021; 116(7): 1426. CrossRef
Multidetector computed tomography three-dimensional and multiplanar reconstruction diagnosis of a rare cause of gastrointestinal bleeding: A case report
Yong Cai, Xiao-Bo Chen, Da-Hai Mai, Ping Wu, Yong-Hai Chen, Hua Chen
World Journal of Gastrointestinal Surgery.2021; 13(1): 87. CrossRef
Effectiveness and safety of endoscopic treatment for duodenal variceal bleeding: a systematic review
Wan Yipeng, Liu Cong, Wan Sizhe, Huang Chenkai, Wang Anjiang, Zhu Xuan
European Journal of Gastroenterology & Hepatology.2021; 33(4): 461. CrossRef
Small bowel bleeding
Stefania Chetcuti Zammit, Reena Sidhu
Current Opinion in Gastroenterology.2018; 34(3): 165. CrossRef
A case report of bleeding from a duodenal varix
Vincent Khor, Yuen Soon, Lwin Aung
International Journal of Surgery Case Reports.2018; 49(C): 205. CrossRef
Endoscopic Sclerotherapy with a Large Volume of High Concentration of Cyanoacrylate for Jejunal Variceal Bleeding bys Single-Balloon Enteroscopy
Jyong-Hong Lee, Chih-Sheng Wu, Jen-Hsuan Huang
Medicina.2018; 54(5): 68. CrossRef
Duodenal variceal bleed: an unusual cause of upper gastrointestinal bleed and a difficult diagnosis to make
Shradha Bhagani, Conchubhair Winters, Sulleman Moreea
BMJ Case Reports.2017; 2017: bcr2016218669. CrossRef
Complete Eradication of Bleeding Duodenal Varices with Endoscopic Polydocanol Sclerotherapy
Safak Meric Ozgenel, Tuncer Temel,, Abdülvahhap Aktas, Aysegül Özakyol
Euroasian Journal of Hepato-Gastroenterology.2016; 6(2): 176. CrossRef
Endoscopic therapies for small-bowel bleeding
Jennifer L. Maranki, Oleh Haluszka
Techniques in Gastrointestinal Endoscopy.2012; 14(2): 106. CrossRef